Protagonist Therapeutics, Inc.
PTGX
$46.28
$0.481.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3,550.01% | 12.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3,550.01% | 12.19% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 3,550.01% | 12.19% | |||
| SG&A Expenses | -11.85% | 7.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.92% | 7.37% | |||
| Operating Income | 405.84% | -6.86% | |||
| Income Before Tax | 497.45% | -7.47% | |||
| Income Tax Expenses | 573.81% | 37.87% | |||
| Earnings from Continuing Operations | 496.49% | -8.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 496.49% | -8.47% | |||
| EBIT | 405.84% | -6.86% | |||
| EBITDA | 407.84% | -6.93% | |||
| EPS Basic | 492.90% | -7.67% | |||
| Normalized Basic EPS | 493.86% | -6.68% | |||
| EPS Diluted | 467.65% | -8.00% | |||
| Normalized Diluted EPS | 469.67% | -6.68% | |||
| Average Basic Shares Outstanding | 0.91% | 0.75% | |||
| Average Diluted Shares Outstanding | 7.51% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||